Glenmark
A new way for a new world

September 27, 2013

The Manager
Listing Dept,
The National Stock Exchange of India Ltd
Plot No. C/1,G Block
Bandra Kurla Complex
Bandra (E) Mumbai-400051

Sub: Glenmark Pharmaceuticals Ltd. receives a small research fee payment from Forest Laboratories Inc.

This is to inform you that Glenmark Pharmaceuticals Ltd. announced today that it has received a small research fee payment from Forest Laboratories Inc. on a collaboration for the development of novel mPGES-1 inhibitors to treat chronic inflammatory conditions to support the next phase of work. **Glenmark is expecting an additional payment to support the advancement of the programme**. Forest has an exclusive option to obtain license rights to the program upon the completion of pre-clinical trials. Under the terms of the agreement signed in FY 2012-13, Forest had made USD $6 million upfront payment to Glenmark and also made an additional $3 million to support the next phase of work for the development of novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.

Sanjay Kumar Chowdhary
Company Secretary &Compliance Officer

Tel: 4018 9999 / 4018 9879
Fax No: 4018 9986 (Legal & Secretarial Dept.)